NCT05139004View on ClinicalTrials.gov

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

June 13, 2027

Study Completion Date

June 13, 2027

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeSecondary Acute Myeloid Leukemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo AHSCT

BIOLOGICAL

Basiliximab

Given IV

DRUG

Fludarabine Phosphate

Given IV

DRUG

Indium In 111-DOTA-Basiliximab

Given IV

DRUG

Melphalan

Given IV

BIOLOGICAL

Palifermin

Given IV

RADIATION

Total Lymphoid Irradiation

Undergo TMLI

RADIATION

Total Marrow Irradiation

Undergo TMLI

BIOLOGICAL

Yttrium Y 90 Basiliximab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER